Peptide Library

Human study PLS-00002

Phase 1 safety, tolerability and pharmacokinetics of PL 14736 (BPC-157) in healthy male volunteers

Other design · Not reported participants enrolled

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Veljaca M, et al. Safety, Tolerability and Pharmacokinetics of PL 14736, a Novel Agent for Treatment of Ulcerative Colitis, in Healthy Male Volunteers. Gut. 2003;51:A309 (meeting abstract; with a 2002 IUPHAR-GI abstract).conference abstract

Design and participants

Design
Other design
Population
Healthy male volunteers
Conditions
Healthy volunteers (agent developed for ulcerative colitis)
Setting
Phase 1 clinical pharmacology study (setting not further described)
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

  • PL 14736 (BPC-157) (intervention) · bpc-157 · PL 14736, the development code for BPC-157 · Not reported assigned

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Safety and tolerability

unclear outcome · safety

  • No results reported.

Pharmacokinetics

unclear outcome · surrogate

  • No results reported.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

  • abstract only: Only a meeting-abstract citation is available. No abstract text, methods or results are in the record.
  • inappropriate population: Participants were healthy male volunteers, not patients with pain, tendon, muscle or gastrointestinal conditions.
  • other: Design details are not reported: randomization, presence of a placebo arm, sample size, route and duration are all unknown.
  • selective reporting: The study appears only as conference abstracts with no full publication, so complete outcome reporting cannot be verified.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

  • Insufficient information to assess Adverse events, serious adverse events and discontinuations

Where each value comes from

  • arms: EXTERNAL report-1, citation (citation title (PL 14736)) · extracted by AI (automated, not verified by a person) · abstract only
  • design: EXTERNAL report-1, citation (citation title (Safety, Tolerability and Pharmacokinetics)) · extracted by AI (automated, not verified by a person) · abstract only
  • limitations: EXTERNAL report-1, citation (citation note (meeting abstract)) · extracted by AI (automated, not verified by a person) · abstract only
  • outcomes: EXTERNAL report-1, citation (citation title (safety, tolerability, pharmacokinetics)) · extracted by AI (automated, not verified by a person) · abstract only
  • population: EXTERNAL report-1, citation (citation title (healthy male volunteers)) · extracted by AI (automated, not verified by a person) · abstract only

  • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).